Simplify Asset Management Inc. Takes Position in Novo Nordisk A/S $NVO

Simplify Asset Management Inc. purchased a new stake in Novo Nordisk A/S (NYSE:NVO) in the 1st quarter, HoldingsChannel reports. The institutional investor purchased 327,357 shares of the company’s stock, valued at approximately $12,030,000. Novo Nordisk A/S makes up 0.2% of Simplify Asset Management Inc.’s investment portfolio, making the stock its 17th biggest position.

A number of other hedge funds have also recently added to or reduced their stakes in NVO. Quotient Wealth Partners LLC raised its holdings in Novo Nordisk A/S by 2.0% in the 4th quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock valued at $463,000 after acquiring an additional 177 shares in the last quarter. Certuity LLC grew its holdings in shares of Novo Nordisk A/S by 3.6% during the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after purchasing an additional 177 shares in the last quarter. Oakworth Capital Inc. grew its holdings in shares of Novo Nordisk A/S by 41.6% during the 4th quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock worth $31,000 after purchasing an additional 182 shares in the last quarter. True North Advisors LLC increased its position in shares of Novo Nordisk A/S by 3.9% in the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock worth $270,000 after purchasing an additional 199 shares during the period. Finally, Asio Capital LLC increased its position in shares of Novo Nordisk A/S by 3.9% in the fourth quarter. Asio Capital LLC now owns 5,386 shares of the company’s stock worth $274,000 after purchasing an additional 200 shares during the period. Institutional investors own 11.54% of the company’s stock.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Several valuation-focused articles say Novo Nordisk may be undervalued, with DCF and market-multiple checks suggesting the stock could trade below intrinsic value. Analysts also point to Medicare GLP-1 coverage as a potential demand tailwind for Ozempic/Wegovy and the broader GLP-1 franchise. Novo Nordisk (NVO) Stock May Be 48% Undervalued On Medicare GLP 1 Coverage
• Positive Sentiment: Research highlighting the fast-growing global diabetes drug market reinforces Novo Nordisk’s long-term growth opportunity, with GLP-1 therapies still central to the company’s competitive position. Novo Nordisk (NVO) Is At The Center Of A Fast Growing Diabetes Drug Market
• Positive Sentiment: Independent valuation checks and a strong GF Score also suggest Novo Nordisk remains attractive despite recent volatility, supporting the case that the stock may have room to recover further. Novo Nordisk AS (NVO) Stock Up 3.4% and Still Undervalued — GF Score: 76/100

Novo Nordisk A/S Stock Down 0.1%

Shares of NVO opened at $50.39 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $71.79. The stock has a market capitalization of $224.97 billion, a price-to-earnings ratio of 11.83, a PEG ratio of 4.60 and a beta of 0.77. The stock has a fifty day moving average of $44.70 and a 200-day moving average of $45.85.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion for the quarter. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on NVO. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Wolfe Research began coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating on the stock. Weiss Ratings cut shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, April 22nd. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Finally, Sanford C. Bernstein started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price objective on the stock. Five analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.